Article Details

TG Therapeutics: Ublituximab Could Achieve $1 Billion In Annual Sales By Year-End 2024

Retrieved on: 2022-12-15 19:19:10

Tags for this article:

Click the tags to see associated articles and topics

TG Therapeutics: Ublituximab Could Achieve $1 Billion In Annual Sales By Year-End 2024. View article details on hiswai:

Excerpt

As a 3rd generation anti-CD20 monoclonal antibody, ublituximab is ... Anti-CD20 monoclonal antibodies are critically important to patient care in ...

Article found on: seekingalpha.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up